{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:28:55Z","timestamp":1707524935139},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"DOI":"10.7759\/cureus.36146","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T17:27:53Z","timestamp":1678814873000},"source":"Crossref","is-referenced-by-count":0,"title":["The Roles and Challenges of Advanced Therapies in the Management of Refractory Immune Thrombocytopenia: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Beatrice E","family":"Torere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry O","family":"Aiwuyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Weigold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nosakhare","family":"Ilerhunmwuwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Belousova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030024","article-title":"Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia","volume":"3","author":"Stasi R","year":"2006","unstructured":"Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med. 2006, 3:e24. 10.1371\/journal.pmed.0030024","journal-title":"PLoS Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero F","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al.. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009, 113:2386-93. 10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04547.x","article-title":"Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients","volume":"122","author":"Neylon AJ","year":"2003","unstructured":"Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003, 122:966-74. 10.1046\/j.1365-2141.2003.04547.x","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10305","article-title":"Steroid-refractory chronic idiopathic thrombocytopenic purpura responding to combination therapy with eltrombopag and rituximab","volume":"12","author":"Ahmed M","year":"2020","unstructured":"Ahmed M, Yassin MA, Abdelmahmuod E. Steroid-refractory chronic idiopathic thrombocytopenic purpura responding to combination therapy with eltrombopag and rituximab. Cureus. 2020, 12:e10305. 10.7759\/cureus.10305","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan D","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, et al.. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019, 3:3780-817. 10.1182\/bloodadvances.2019000812","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert C","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al.. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019, 3:3829-66. 10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-742353","article-title":"Splenectomy for immune thrombocytopenia: down but not out","volume":"131","author":"Chaturvedi S","year":"2018","unstructured":"Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018, 131:1172-82. 10.1182\/blood-2017-09-742353","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198105073041904","article-title":"Chronic idiopathic thrombocytopenic purpura","volume":"304","author":"McMillan R","year":"1981","unstructured":"McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981, 304:1135-47. 10.1056\/NEJM198105073041904","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9083","article-title":"Immune thrombocytopenia purpura secondary to COVID-19","volume":"12","author":"Bennett J","year":"2020","unstructured":"Bennett J, Brown C, Rouse M, Hoffmann M, Ye Z. Immune thrombocytopenia purpura secondary to COVID-19. Cureus. 2020, 12:e9083. 10.7759\/cureus.9083","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17024","article-title":"Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series","volume":"190","author":"Mah\u00e9vas M","year":"2020","unstructured":"Mah\u00e9vas M, Moulis G, Andres E, et al.. Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020, 190:e224-9. 10.1111\/bjh.17024","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-021-01019-7","article-title":"Frequently relapsing post-COVID-19 immune thrombocytopenia","volume":"3","author":"Serrano C","year":"2021","unstructured":"Serrano C, Espa\u00f1ol I, Cascales A, Moraleda JM. Frequently relapsing post-COVID-19 immune thrombocytopenia. SN Compr Clin Med. 2021, 3:2389-92. 10.1007\/s42399-021-01019-7","journal-title":"SN Compr Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16368","article-title":"Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland Clinic experience","volume":"61","author":"Kewan T","year":"2021","unstructured":"Kewan T, Gunaratne TN, Mushtaq K, Alayan D, Daw H, Haddad A. Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland Clinic experience. Transfusion. 2021, 61:2014-8. 10.1111\/trf.16368","journal-title":"Transfusion"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27133","article-title":"Persistent relapsing immune thrombocytopenia following COVID-19 infection","volume":"14","author":"Boehm BA","year":"2022","unstructured":"Boehm BA, Packer CD. Persistent relapsing immune thrombocytopenia following COVID-19 infection. Cureus. 2022, 14:e27133. 10.7759\/cureus.27133","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2326-12-2","article-title":"Patient-reported treatment burden of chronic immune thrombocytopenia therapies","volume":"12","author":"Brown TM","year":"2012","unstructured":"Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012, 12:2. 10.1186\/1471-2326-12-2","journal-title":"BMC Blood Disord"},{"key":"ref15","unstructured":"American Society of Hematology. Case study. chronic immune thrombocytopenia purpura. (2023). Accessed: February 14, 2023: https:\/\/www.hematology.org\/education\/trainees\/fellows\/case-studies\/chronic-immune-thrombocytopenia-purpura."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16775","article-title":"Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic","volume":"189","author":"Pavord S","year":"2020","unstructured":"Pavord S, Thachil J, Hunt BJ, et al.. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2020, 189:1038-43. 10.1111\/bjh.16775","journal-title":"Br J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan D","year":"2022","unstructured":"Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022, 76:103820. 10.1016\/j.ebiom.2022.103820","journal-title":"EBioMedicine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/140607-the-roles-and-challenges-of-advanced-therapies-in-the-management-of-refractory-immune-thrombocytopenia-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:23Z","timestamp":1707508523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/140607-the-roles-and-challenges-of-advanced-therapies-in-the-management-of-refractory-immune-thrombocytopenia-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.36146","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}